1. Structural Biology and Molecular Biophysics
  2. Cell Biology

Specific cancer associated mutations in the switch III-region of Ras increase tumorigenicity by nanocluster augmentation

  1. Maja Solman
  2. Alessio Ligabue
  3. Olga Blazevits
  4. Alok Jaiswal
  5. Yong Zhou
  6. Hong Liang
  7. Benoit Lectez
  8. Kari Kopra
  9. Camilo Guzman
  10. Harri Härmä
  11. John F Hancock
  12. Tero Aittokallio
  13. Daniel Abankwa  Is a corresponding author
  1. Åbo Akademi University, Finland
  2. University of Helsinki, Finland
  3. University of Texas Health Science Center at Houston, United States
  4. University of Turku, Finland
https://doi.org/10.7554/eLife.08905
Share this article
Cite this article
  1. Maja Solman
  2. Alessio Ligabue
  3. Olga Blazevits
  4. Alok Jaiswal
  5. Yong Zhou
  6. Hong Liang
  7. Benoit Lectez
  8. Kari Kopra
  9. Camilo Guzman
  10. Harri Härmä
  11. John F Hancock
  12. Tero Aittokallio
  13. Daniel Abankwa
(2015)
Specific cancer associated mutations in the switch III-region of Ras increase tumorigenicity by nanocluster augmentation
eLife 4:e08905.
https://doi.org/10.7554/eLife.08905
  2. Download BibTeX
  3. Download .RIS

Abstract

Hotspot mutations of Ras drive cell transformation and tumorigenesis. Less frequent mutations in Ras are poorly characterized for their oncogenic potential. Yet insight into their mechanism of action may point to novel opportunities to target Ras. Here we show that several cancer-associated mutations in the switch III region moderately increase Ras activity in all isoforms. Mutants are biochemically inconspicuous, while their clustering into nanoscale signaling complexes on the plasma membrane, termed nanocluster, is augmented. Nanoclustering dictates downstream effector recruitment, MAPK-activity and tumorigenic cell proliferation. Our results describe an unprecedented mechanism of signaling protein activation in cancer.

Article and author information

Author details

  1. Maja Solman

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  2. Alessio Ligabue

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  3. Olga Blazevits

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  4. Alok Jaiswal

    Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  5. Yong Zhou

    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Hong Liang

    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Benoit Lectez

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  8. Kari Kopra

    Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  9. Camilo Guzman

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  10. Harri Härmä

    Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.

  11. John F Hancock

    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. Tero Aittokallio

    Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  13. Daniel Abankwa

    Turku Centre for Biotechnology, Åbo Akademi University, Turku, Finland
    For correspondence
    daniel.abankwa@btk.fi
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Jonathan A Cooper, Fred Hutchinson Cancer Research Center, United States

Version history

  1. Received: May 21, 2015
  2. Accepted: August 13, 2015
  3. Accepted Manuscript published: August 14, 2015 (version 1)
  4. Version of Record published: September 11, 2015 (version 2)

Copyright

© 2015, Solman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,296
    views
  • 558
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Maja Solman
  2. Alessio Ligabue
  3. Olga Blazevits
  4. Alok Jaiswal
  5. Yong Zhou
  6. Hong Liang
  7. Benoit Lectez
  8. Kari Kopra
  9. Camilo Guzman
  10. Harri Härmä
  11. John F Hancock
  12. Tero Aittokallio
  13. Daniel Abankwa
(2015)
Specific cancer associated mutations in the switch III-region of Ras increase tumorigenicity by nanocluster augmentation
eLife 4:e08905.
https://doi.org/10.7554/eLife.08905

Share this article

https://doi.org/10.7554/eLife.08905

Categories and tags

Research organism

Further reading

    1. Structural Biology and Molecular Biophysics

    Plasticity of the proteasome-targeting signal Fat10 enhances substrate degradation

    Hitendra Negi, Aravind Ravichandran ... Ranabir Das
    Research Article

    The proteasome controls levels of most cellular proteins, and its activity is regulated under stress, quiescence, and inflammation. However, factors determining the proteasomal degradation rate remain poorly understood. Proteasome substrates are conjugated with small proteins (tags) like ubiquitin and Fat10 to target them to the proteasome. It is unclear if the structural plasticity of proteasome-targeting tags can influence substrate degradation. Fat10 is upregulated during inflammation, and its substrates undergo rapid proteasomal degradation. We report that the degradation rate of Fat10 substrates critically depends on the structural plasticity of Fat10. While the ubiquitin tag is recycled at the proteasome, Fat10 is degraded with the substrate. Our results suggest significantly lower thermodynamic stability and faster mechanical unfolding in Fat10 compared to ubiquitin. Long-range salt bridges are absent in the Fat10 structure, creating a plastic protein with partially unstructured regions suitable for proteasome engagement. Fat10 plasticity destabilizes substrates significantly and creates partially unstructured regions in the substrate to enhance degradation. NMR-relaxation-derived order parameters and temperature dependence of chemical shifts identify the Fat10-induced partially unstructured regions in the substrate, which correlated excellently to Fat10-substrate contacts, suggesting that the tag-substrate collision destabilizes the substrate. These results highlight a strong dependence of proteasomal degradation on the structural plasticity and thermodynamic properties of the proteasome-targeting tags.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics

    Special Issue: Allosteric regulation of kinase activity

    Amy H Andreotti, Volker Dötsch
    Editorial

    The articles in this special issue highlight how modern cellular, biochemical, biophysical and computational techniques are allowing deeper and more detailed studies of allosteric kinase regulation.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics

    Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling

    Samuel C Griffiths, Jia Tan ... Hsin-Yi Henry Ho
    Research Article Updated

    The receptor tyrosine kinase ROR2 mediates noncanonical WNT5A signaling to orchestrate tissue morphogenetic processes, and dysfunction of the pathway causes Robinow syndrome, brachydactyly B, and metastatic diseases. The domain(s) and mechanisms required for ROR2 function, however, remain unclear. We solved the crystal structure of the extracellular cysteine-rich (CRD) and Kringle (Kr) domains of ROR2 and found that, unlike other CRDs, the ROR2 CRD lacks the signature hydrophobic pocket that binds lipids/lipid-modified proteins, such as WNTs, suggesting a novel mechanism of ligand reception. Functionally, we showed that the ROR2 CRD, but not other domains, is required and minimally sufficient to promote WNT5A signaling, and Robinow mutations in the CRD and the adjacent Kr impair ROR2 secretion and function. Moreover, using function-activating and -perturbing antibodies against the Frizzled (FZ) family of WNT receptors, we demonstrate the involvement of FZ in WNT5A-ROR signaling. Thus, ROR2 acts via its CRD to potentiate the function of a receptor super-complex that includes FZ to transduce WNT5A signals.